These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29156488)

  • 21. Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.
    Sorich MJ; Rowland A; Hopkins AM
    Melanoma Res; 2020 Jun; 30(3):268-271. PubMed ID: 31425480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
    Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
    Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
    Ascierto PA; Ribas A; Larkin J; McArthur GA; Lewis KD; Hauschild A; Flaherty KT; McKenna E; Zhu Q; Mun Y; Dréno B
    J Transl Med; 2020 Aug; 18(1):294. PubMed ID: 32746839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
    Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
    Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF
    Dréno B; Ascierto PA; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Bartley K; Karagiannis T; Chang I; Rooney I; Koralek DO; Larkin J; McArthur GA; Ribas A
    Br J Cancer; 2018 Mar; 118(6):777-784. PubMed ID: 29438370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma.
    Zoratti MJ; Devji T; Levine O; Thabane L; Xie F
    Cancer Treat Rev; 2019 Mar; 74():43-48. PubMed ID: 30798169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with
    Yan Y; Wongchenko MJ; Robert C; Larkin J; Ascierto PA; Dréno B; Maio M; Garbe C; Chapman PB; Sosman JA; Shi Z; Koeppen H; Hsu JJ; Chang I; Caro I; Rooney I; McArthur GA; Ribas A
    Clin Cancer Res; 2019 Jun; 25(11):3239-3246. PubMed ID: 30824584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cobimetinib and vemurafenib for the treatment of melanoma.
    Boespflug A; Thomas L
    Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
    Cai C; Yunusa I; Tarhini A
    JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study.
    de la Cruz-Merino L; Di Guardo L; Grob JJ; Venosa A; Larkin J; McArthur GA; Ribas A; Ascierto PA; Evans JTR; Gomez-Escobar A; Barteselli G; Eng S; Hsu JJ; Uyei A; Dréno B
    J Transl Med; 2017 Jun; 15(1):146. PubMed ID: 28646893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
    Cao Y; Chan KI; Xiao G; Chen Y; Qiu X; Hao H; Mak SC; Lin T
    BMC Cancer; 2019 Oct; 19(1):1022. PubMed ID: 31664962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study.
    Luke JJ; Ghate SR; Kish J; Lee CH; McAllister L; Mehta S; Ndife B; Feinberg BA
    Future Oncol; 2019 Sep; 15(25):2933-2942. PubMed ID: 30799646
    [No Abstract]   [Full Text] [Related]  

  • 34. Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
    Livingstone E; Gogas H; Kandolf-Sekulovic L; Meier F; Eigentler TK; Ziemer M; Terheyden PAM; Gesierich AH; Herbst RA; Kähler KC; Ziogas DC; Mijuskovic Z; Garzarolli M; Garbe C; Roesch A; Ugurel S; Gutzmer R; Grob JJ; Kiecker F; Utikal J; Windemuth-Kieselbach C; Eckhardt S; Zimmer L; Schadendorf D
    Eur J Cancer; 2023 Sep; 190():112941. PubMed ID: 37482012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cobimetinib plus atezolizumab in BRAF
    Gogas H; Dréno B; Larkin J; Demidov L; Stroyakovskiy D; Eroglu Z; Francesco Ferrucci P; Pigozzo J; Rutkowski P; Mackiewicz J; Rooney I; Voulgari A; Troutman S; Pitcher B; Guo Y; Yan Y; Castro M; Mulla S; Flaherty K; Arance A
    Ann Oncol; 2021 Mar; 32(3):384-394. PubMed ID: 33309774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.
    Engel S; Luessi F; Henning B; Bittner S; Loquai C; Zipp F
    Ann Oncol; 2019 Jun; 30(6):1014-1016. PubMed ID: 30911762
    [No Abstract]   [Full Text] [Related]  

  • 37. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
    Amaral T; Nouri N; Garbe C
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.
    Hopkins AM; Van Dyk M; Rowland A; Sorich MJ
    Pigment Cell Melanoma Res; 2019 Jul; 32(4):576-583. PubMed ID: 30758912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
    Simeone E; Scognamiglio G; Capone M; Giannarelli D; Grimaldi AM; Mallardo D; Madonna G; Curvietto M; Esposito A; Sandomenico F; Sabbatino F; Bayless NL; Warren S; Ong S; Botti G; Flaherty KT; Ferrone S; Ascierto PA
    J Transl Med; 2021 Jan; 19(1):17. PubMed ID: 33407577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early access program: MELANIS study.
    Meyer N; Pérol D; Duval-Modeste AB; El Adaoui L; Lelarge Y; Niarra R; Mateus C
    Melanoma Res; 2022 Aug; 32(4):269-277. PubMed ID: 35635532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.